XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Bioniz
Common Stock
Common Stock
Bioniz
Additional Paid-in Capital
Additional Paid-in Capital
Bioniz
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at Dec. 31, 2021 $ 66,505   $ 2   $ 176,618   $ (138) $ (109,977)
Balance, Shares at Dec. 31, 2021     29,455,668          
Issuance of common stock   $ 22,542   $ 1   $ 22,541    
Issuance of common stock, Shares       4,820,230        
Vesting of restricted stock liability 18       18      
Stock-based compensation expense 1,298       1,298      
Comprehensive income (loss) (316)           (316)  
Net loss (37,417)             (37,417)
Balance at Mar. 31, 2022 52,630   $ 3   200,475   (454) (147,394)
Balance, Shares at Mar. 31, 2022     34,275,898          
Balance at Dec. 31, 2022 31,942   $ 3   204,268   76 (172,405)
Balance, Shares at Dec. 31, 2022     34,414,149          
Stock-based compensation expense 1,038       1,038      
Comprehensive income (loss) 229           229  
Net loss (3,940)             (3,940)
Balance at Mar. 31, 2023 $ 29,269   $ 3   $ 205,306   $ 305 $ (176,345)
Balance, Shares at Mar. 31, 2023     34,414,149